Targeting Costimulatory Pathways in Systemic Sclerosis.

Front Immunol · 2018 · PMC6305435 · PMID 30619351

Europe PMC DOI

hedged sentence

0.0625

closest p · 1.3× alpha

0.0625

boldest claim

The sentences

showed a trendp = 0.0625so close (0.05 < p ≤ 0.1)

At week 24, subjects randomized to abatacept showed a trend toward improvement in mRSS (−8.6 p = 0.0625).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.